Scholars@Duke
Erika J Crosby

Erika J Crosby

Assistant Professor in Surgery
Surgery, Surgical Sciences
203 Research Drive, MSRB1 Box 2606, Durham, NC 27710
MSRB1 Room 288, Durham, NC 27710

Scholarly Works - Conferences

Abstract B041: GLP-1 receptor agonists associated with improved response to immune checkpoint inhibitors in solid tumors: a multi-institutional retrospective cohort study

Conference Cancer Immunology Research · February 18, 2026 AbstractIntroduction:Glucagon-like peptide-1 (GLP-1) receptor agonists are increasingly utilized for Type 2 Diabetes Mellitus ( ... Full text Cite

Abstract C071: Obesity impairs anti-tumor responses to breast cancer vaccination

Conference Cancer Immunology Research · February 18, 2026 AbstractWhile advances in immunotherapy have improved treatment of breast cancer, many patients do not respond to current immunotherapies, there is not a reliable predictor of immunotherapy efficacy, and ... Full text Cite

Abstract A005: Utility of an oncogene-driven spontaneous triple-negative breast cancer model for immunotherapeutic testing

Conference Cancer Immunology Research · February 18, 2026 AbstractOne in eight women will develop breast cancer in their lifetime and it is the second leading cause of cancer-related deaths among women. Breast cancer is a heterogeneous disease with multiple subt ... Full text Cite

Abstract B074: scRNA-seq from FFPE tissue resolves the tumor microenvironment of intraductal papillary mucinous neoplasms

Conference Cancer Research · September 28, 2025 AbstractIntraductal papillary mucinous neoplasms (IPMN) are precancerous cysts representing the only radiographically identifiable precursor to pa ... Full text Cite

Abstract A009: Characterizing the pre-metastatic liver in PDAC patients using scRNA-seq of FFPE tissue

Conference Cancer Research · September 28, 2025 AbstractPancreatic ductal adenocarcinoma (PDAC) remains an essentially incurable disease. Even among patients considered for curative-intent surge ... Full text Cite

Abstract A104: Targeting the CXCR3 axis in HER2+ breast cancer with mRNA Lipid Nanoparticles to enhance anti-tumor immunity

Conference Cancer Immunology Research · February 23, 2025 AbstractBreast cancer (BC) is the most frequently diagnosed cancer in women worldwide with more than 2 million new cases in 2020. The efficacy of immune checkpoint blockade (ICB) for BC is limited, with resp ... Full text Cite

Abstract B052: Single-cell and spatial analysis of the immune landscape unveils a subset of potentially tumor-reactive T cells in patients with localized PDAC

Conference Cancer Research · September 15, 2024 AbstractEven in its localized stages, pancreatic ductal adenocarcinoma (PDAC) is virtually incurable, characterized by early dissemination and disease recurrence. The liver is the most common site of metasta ... Full text Cite

Abstract C004: A window-of-opportunity trial using neoadjuvant hepatic artery chemotherapy for patients with localized pancreas cancer: Interim analysis of safety and feasibility

Conference Cancer Research · September 15, 2024 AbstractLess than 20% of patients diagnosed with pancreatic cancer will present with localized disease and receive both resection and systemic therapy. Within this group of patients, actual 10-year survival ... Full text Cite

Abstract PO3-26-06: A self-replicating RNA Precision Immunotherapeutic for Overcoming Resistance to Endocrine Therapy in Estrogen Receptor Positive Breast Cancer (ER+BC)

Conference Cancer Research · May 2, 2024 AbstractAdvanced or metastatic ER+HER2- breast cancer (ER+BC) is an incurable disease. Standard 1L therapy (SOC) utilizes endocrine blockade with a nonsteroidal aromatase inhibitor (NSAI) combined with a CDK ... Full text Cite

Abstract 2458: Targeting the CXCR3 axis in HER2+ breast cancer to enhance anti-tumor immunity

Conference Cancer Research · March 22, 2024 AbstractBreast cancer (BC) is the most frequently diagnosed cancer in women worldwide with more than 2 million new cases in 2020. The efficacy of immunotherapies for BC is limited, with response rates of &am ... Full text Cite

Abstract 5296: Enhancing the strength and durability of vaccine-induced anti-tumor immunity with CD27 agonism of CD4+ T cells

Conference Cancer Research · March 22, 2024 AbstractDespite encouraging early phase clinical trials, decades of research have yet to yield effective cancer vaccine immunotherapies. To determine potential markers for success, we performed a follow-up s ... Full text Cite

Abstract B022: A platform to characterize hepatic immunity reveals variation in hepatic infiltration of tumor expanded T cells in “localized” PDAC

Conference Cancer Research · January 16, 2024 AbstractEven in its earliest stages, pancreatic ductal adenocarcinoma (PDAC) is an essentially incurable disease due to the presence of disseminated, yet radiographically occult cancer cells in the setting o ... Full text Cite

Abstract 2732: A self-replicating RNA precision medicine approach to therapeutic protein delivery of narrow therapeutic index biomolecules

Conference Cancer Research · April 4, 2023 AbstractProtein drug replacement using nucleic acid technologies has been a sought-after solution for in situ production of proteins with poor half-lives and challenging manufacturability. Linear mRNA approa ... Full text Cite

Abstract 6403: A self-replicating RNA precision medicine approach to overcoming resistance to endocrine therapy in ER+BC

Conference Cancer Research · April 4, 2023 AbstractDrug resistance remains the major driving factor behind the clinical failure of targeted therapeutics. Current oncology precision medicine approaches rely on targeting known acquired resistance mutat ... Full text Cite

Abstract 696: Sensitizing breast cancers to immune checkpoint inhibitors through CD27 agonism and vaccination against tumor-associated antigen

Conference Cancer Research · April 4, 2023 AbstractProject objective: Despite the recent revolution in immune checkpoint inhibitors (ICIs), only modest improvement in overall survival and likely caused by not enough potent cellular immunity among BC ... Full text Cite

Ultrasound Enhanced Perfusion and Drug Penetration for Intratumoral Immunotherapy Using a Needle Ultrasound Transducer - a Phantom Study

Conference IEEE International Ultrasonics Symposium Ius · January 1, 2023 Intratumoral immunotherapy is a promising cancer treatment approach that can initiate durable anti-tumor responses and avoid potential off-target toxicities. However, direct intratumoral injection remains challenging owing to elevated solid stress and inte ... Full text Cite

Intracorporeal Sonoporation-Induced Drug/Gene Delivery Using a Catheter Ultrasound Transducer

Conference IEEE International Ultrasonics Symposium Ius · January 1, 2022 Ultrasound (US) has been recently demonstrated promising in cancer immunotherapy. By virtue of microbubble-mediated cavitation, US can induce temporary pores in the cell membrane to enhance drug/gene delivery and this process is termed sonoporation. Curren ... Full text Cite

Abstract 904: Stimulation and expansion of oncogene-reactive tumor infiltrating T cells through combined Ad-HER2Δ16 vaccination and anti-PD1 enable anti-tumor responses against established HER2 BC

Conference Cancer Research · August 15, 2020 AbstractDespite promising advances, overcoming immune suppression and driving productive immune responses in the tumor microenvironment remains a significant challenge. Using a spontaneous breast cancer mode ... Full text Cite

Abstract P2-09-16: CD8 T cells induced by novel alphaviral vector predict improved progression free survival in advanced HER2+ breast cancer patients

Conference Cancer Research · February 15, 2019 AbstractBackground: Immune-based therapy for metastatic breast cancer has had limited success. Strategies to augment adaptive immunity include vaccines targeting genomic amplifications like Human Epidermal G ... Full text Cite

Abstract A22: Augmentation of a novel adenoviral vaccine strategy by checkpoint inhibitors

Conference Cancer Immunology Research · September 1, 2018 AbstractThe immunologic hurdles for a vaccine targeting cancer are much higher than for those targeting an infectious disease. The profoundly immunosuppressive tumor microenvironment, the lack of microbial d ... Full text Cite

Abstract A38: Checkpoint blockade elicits unique T cell expansion to promote tumor regression

Conference Cancer Immunology Research · March 1, 2017 AbstractWhile PD-1 and CTLA-4 immune checkpoint antibodies have led to durable clinical activity in certain cancers, only a fraction of patients exhibit responses. In these responsive tumors, PD-1 and CTLA-4 ... Full text Cite

Abstract P2-04-27: CTLA-4 and PD-1 checkpoint inhibitors enhance individually tailored adaptive anti-tumor immune responses to overcome tumor immunosuppression and effectively treat triple-negative breast cancer

Conference Cancer Research · February 15, 2017 AbstractDespite a lack of unifying drivers in Triple-Negative Breast Cancer (TNBC), our lab and others have uncovered that these cancers have elevated expression of inflammatory genes and immunosuppressive m ... Full text Cite